Gilteritinib
Sign in to save this workspacePrimary targets: FLT3 · FDA status: FDA Approved
Selectivity scorecard
KISS
88.97
Gini
0.506
CATDS
0.007
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Gilteritinib. Strongest target: RET at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RET | 100.0% | 0.0% |
| 2 | TYK1_LTK | 99.7% | 0.3% |
| 3 | ROS_ROS1 | 99.6% | 0.4% |
| 4 | ALK | 99.5% | 0.5% |
| 5 | FLT3 | 99.2% | 0.8% |
| 6 | TRKC | 99.0% | 1.0% |
| 7 | TNIK | 98.8% | 1.2% |
| 8 | AXL | 98.7% | 1.3% |
| 9 | FLT4_VEGFR3 | 98.5% | 1.5% |
| 10 | C_MER | 98.4% | 1.6% |
| 11 | LOK_STK10 | 98.3% | 1.7% |
| 12 | MLK3_MAP3K11 | 97.4% | 2.6% |
| 13 | LRRK2 | 97.2% | 2.8% |
| 14 | STK22D_TSSK1 | 96.8% | 3.2% |
| 15 | DDR2 | 96.7% | 3.3% |
| 16 | BRK | 96.6% | 3.4% |
| 17 | HPK1_MAP4K1 | 96.6% | 3.4% |
| 18 | FGR | 95.8% | 4.2% |
| 19 | DDR1 | 95.7% | 4.3% |
| 20 | MINK_MINK1 | 95.7% | 4.3% |
Selectivity landscape
Where Gilteritinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Gilteritinib.
Annotations
Sign in to read and post annotations.
Loading…